The cost associated with administering risperidone long-acting injections in the Australian community

The cost associated with administering risperidone long-acting injections in the Australian community

<p>Abstract</p> <p>Background</p> <p>Risperidone long-acting injection (LAI) is mostly administered twice weekly to people with schizophrenia by nurses at community mental health centres (CMHC) or through mobile outreach visits. This study estimates the cost of resource...

Full description

Bibliographic Details
Main Authors:	Hertel Judy, Schrover Rudolf, Lambert Tim, Dalton Andrew, Smith Dell
Format:	Article
Language:	English
Published:	BMC 2011-09-01
Series:	BMC Health Services Research
Online Access:	http://www.biomedcentral.com/1472-6963/11/236

Similar Items

Long acting risperidone in Australian patients with chronic schizophrenia: 24-month data from the e-STAR database
by: Lambert Tim, et al.
Published: (2012-03-01)

Effectiveness of long-acting injectable risperidone in the Korean schizophrenia patients
by: Ciwoniuk, M, et al.
Published: (2007)

Improvement of long-term outcome in schizophrenia: switching to risperidone long-acting injectable
by: Tzanakaki Maria, et al.
Published: (2006-02-01)

Risperidone Long-Acting Injection: Safety and Efficacy in Elderly Patients with Schizophrenia
by: Rosa Catalán, et al.
Published: (2011-05-01)

Efficacy and safety of risperidone long-acting injection in elderly people with schizophrenia
by: Dhiren Singh, et al.
Published: (2009-08-01)

Risperidone Long-Acting Injection: Safety and Efficacy in Elderly Patients with Schizophrenia
by: Rosa Catalán, et al.
Published: (2011-01-01)

Modeling the Choice Between Risperidone Long-Acting Injectable and Generic Risperidone from the Perspective of a Japanese Hospital
by: Yusuke Nakamura, et al.
Published: (2019-08-01)

Effectiveness of injectable risperidone long-acting therapy for schizophrenia: data from the US, Spain, Australia, and Belgium
by: Macfadden Wayne, et al.
Published: (2011-04-01)

Paliperidone palmitate and risperidone long-acting injectable in subjects with schizophrenia recently treated with oral risperidone or other oral antipsychotics
by: Alphs L, et al.
Published: (2013-03-01)

Treatment effectiveness of shifting from risperidone long-acting injectable to first-generation long-acting injectable antipsychotics in patients with schizophrenia
by: Ching- Yin Chang, et al.
Published: (2019-01-01)

The effects of concurrent oral paliperidone or risperidone use with paliperidone long-acting injection
by: Trevor A. Stump, PharmD, BCPP, et al.
Published: (2021-01-01)

Formulation development and pharmacokinetic studies of long acting in situ depot injection of risperidone
by: Vineet Dubey, et al.
Published: (2022-02-01)

Effects of Continuing Oral Risperidone vs. Switching from Risperidone to Risperidone Long-Acting Injection on Cognitive Function in Stable Schizophrenia Patients: A Pilot Study
by: Hikaru Hori, et al.
Published: (2018-03-01)

Three-year clinical experience with the long-acting injectable formulation of the atypical antipsychotic risperidone
by: Giovanoglou Maria, et al.
Published: (2008-04-01)

Cumulative effects of risperidone long acting injection and narrative therapy in treating ethanol dependency
by: Trandafir Maria
Published: (2010-04-01)

Patient perspectives on use of long-acting antipsychotics in bipolar disorder: focus on risperidone injection
by: L Samalin, et al.
Published: (2010-08-01)

The impact of the COVID-19 pandemic on the trend of prescribing long-acting injections of paliperidone and risperidone in Central Serbia
by: Milena Stojkovic, et al.
Published: (2023-12-01)

Treatment-completion rates with olanzapine long-acting injection versus risperidone long-acting injection in a 12-month, open-label treatment of schizophrenia: indirect, exploratory comparisons
by: Ascher-Svanum H, et al.
Published: (2012-05-01)

Poly(Lactic Acid) Block Copolymers with Poly(Hexylene Succinate) as Microparticles for Long-Acting Injectables of Risperidone Drug
by: Iouliana Chrysafi, et al.
Published: (2022-09-01)

Paliperidone Palmitate versus Risperidone Long-Acting Injectable in Patients with Schizophrenia: A Meta-Analysis of Efficacy and Safety
by: Zhao M, et al.
Published: (2023-04-01)

Bipolar Patients and Bullous Pemphigoid after Risperidone Long-Acting Injectable: A Case Report and a Review of the Literature
by: Michele Fabrazzo, et al.
Published: (2021-10-01)

Once-Monthly Subcutaneously Administered Risperidone in the Treatment of Schizophrenia: Patient Considerations
by: Tchobaniouk LV, et al.
Published: (2020-02-01)

Practical dosing guidance for the management of clinician-administered injections of long-acting cabotegravir and rilpivirine
by: Parul Patel, et al.
Published: (2023-12-01)

The Efficacy of a Long-Acting Injectable Selenium Preparation Administered to Pregnant Ewes and Lambs
by: Stanisław Milewski, et al.
Published: (2021-04-01)

Personal and Social Functioning and Health-Related Quality of Life in Patients with Schizophrenia Treated with the Long-Acting Injectable Antipsychotic Risperidone ISM
by: Litman R, et al.
Published: (2023-01-01)

Can multisite clinical trial results change clinical practice? Use of long-acting injectable risperidone nationally in the Veterans Health Administration
by: Robert Rosenheck, et al.
Published: (2023-02-01)

Long-Acting Risperidone Dual Control System: Preparation, Characterization and Evaluation In Vitro and In Vivo
by: Xieguo Yan, et al.
Published: (2021-08-01)

Costs and efficacy ofolanzapine and risperidone in schizophrenia
by: Vittorio Mapelli
Published: (2007-06-01)

A randomized, double-blind, placebo-controlled trial to assess prevention of mood episodes with risperidone long-acting injectable in patients with bipolar I disorder
by: Vieta, E., et al.
Published: (2012)

Risperidone Controlled Release Microspheres Based on Poly(Lactic Acid)-Poly(Propylene Adipate) Novel Polymer Blends Appropriate for Long Acting Injectable Formulations
by: Stavroula Nanaki, et al.
Published: (2018-08-01)

Maintenance therapy with once-monthly administration of long-acting injectable risperidone in patients with schizophrenia or schizoaffective disorder: a pilot study of an extended dosing interval
by: Naessens Ineke, et al.
Published: (2007-01-01)

Assessment of effectiveness measures in patients with schizophrenia initiated on risperidone long-acting therapy: the SOURCE study results
by: Dirani Riad D, et al.
Published: (2011-10-01)

Risperidone in long-term treatment for bipolar disorder
by: Rendell, J, et al.
Published: (2006)

Risperidone in long-term treatment for bipolar disorder.
by: Rendell, J, et al.
Published: (2006)

Adjunctive long-acting risperidone in patients with bipolar disorder who relapse frequently and have active mood symptoms
by: Haskins John T, et al.
Published: (2011-10-01)

Psychiatric Nurses’ Knowledge and Practice Barriers to Administering Long-Acting Injectable (LAI) Antipsychotics in Taiwan: A Mixed-Methods Study
by: Yao-Yu Lin, et al.
Published: (2023-06-01)

Effects of cannabidiol on vacuous chewing movements, plasma glucose and oxidative stress indices in rats administered high dose risperidone
by: Jaiyeola Abiola Kajero, et al.
Published: (2022-11-01)

Efficacy and Safety of Risperidone Microspheres for Injection (Ⅱ) in the Treatment of Patients with Acute Schizophrenia
by: LI Qian, ZHANG Yunshu, YAN Baoping, WANG Jian, MA Yanjuan, WANG Yuan, QIN Yingjie, NA Long, REN Zhiyong, SUN Junwei, DENG Huaili, MA Hongjun, QU Xuehui, ZHOU Nan, SI Tianmei
Published: (2023-11-01)

Administering a subconjunctival injection
by: Sue Stevens
Published: (2009-03-01)

Cabotegravir and Rilpivirine Long-Acting Antiretroviral Therapy Administered Every 2 Months is Cost-Effective for the Treatment of HIV-1 in Spain
by: Santiago Moreno, et al.
Published: (2023-07-01)